PUBLIC RELEASE DATE: 2-Jun-2014 Contact: Robin Dutcher Robin.dutcher@hitchcock.org 603-653-9056 The Geisel School of Medicine at Dartmouth New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations. An international consortium of scientists including investigators at the Institute for Cancer Research in London, the International Agency for Research on Cancer in Lyon, the National Cancer Institute in Bethesda, Harvard, and Dartmouth used integrated results from the 1000 Genomes Project with genetics studies of lung cancer to complete the investigation published on June 1, 2014 in Nature Genetics. The study scanned the genomes of more than 11 thousand individuals of European descent to look for common variations associated with non-small cell carcinoma, a common form of lung cancer. The analysis showed that variations in the BRCA2 and CHEK2 genes can significantly increase an individual's risk for lung cancer. A smoker's chances of developing lung cancer may be doubled if he or she carries the BRCA2 variation. In addition, the TP63 gene, which previously was only associated with lung cancer risk in Asian populations, was associated with risk for adenocarcinoma, a form of non-small cell carcinoma, in those of European … Continue reading →

MANILA, PhilippinesStem cells in a bottle? Too good to be true. The Food and Drug Administration (FDA) has warned the public not to be taken in by the claims about Inner Power Stem Cells Booster, a purported stem cell product being sold and promoted online. In an advisory dated May 29, FDA acting Director General Kenneth Go said the bottled product being marketed on a classified ads website, http://www.olx.ph, was not registered with the FDA either as a drug or a food supplement or human cells, tissues and cellular and tissue-based product (HCT/P). Go also said the online ad carried deceitful health and therapeutic claims not supported by scientific or clinical studies. According to the ad, seaweeds are the primary ingredient of the product combined with root crops, fruits, vegetables, legumes, honey and fructoligosaccharides (food for good bacteria). The prebiotic mixture had been fermented and had produced a byproduct in the form of a jam, the ad said. The ad further claimed that once taken, the product helped in stem cell production by the process of mitosis that would aid in platelet, red and white blood cells production. Sea turtles The ad also claimed that the product was formulated by … Continue reading →

02.06.2014 / 09:00 --------------------------------------------------------------------- Berlin, Germany and Nevada, USA, June 2, 2014 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, today announced that it will participate in the dbAccess German, Swiss & Austrian Conference 2014 held by Deutsche Bank from June 11 until June 13, 2014, in Berlin, Germany. Meeting Details: Speaker: Dr. Ben J. Lipps Date of presentation: Friday, June 13, 2014; 08:00 am CET Location: Hotel Adlon Kempinski, Unter den Linden 77, 10117 Berlin Availability for 1-on-1-meetings: Wednesday, June 11, 2014; 12:30 - 18:30 CET & Friday, June 13, 2014; all day The presentation will be also made available on Magforce's website on http://www.magforce.com. About MagForce AG MagForce AG, listed in the entry standard (MF6), together with its subsidiary MAGFORCE USA, Inc. is a leading medical device company in the field of nanomedicine in oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, … Continue reading →